Beta-carotene supplements: the antioxidant that backfired
Diets rich in colourful fruit and vegetables track with less cancer, so supplement makers bottled beta-carotene. Two large trials in smokers found the pills raised lung cancer and death — the opposite of the hope.
| Group | Value (value) |
|---|---|
| Placebo (reference) | 1 |
| Death, any cause | 1.17 (1.03 to 1.33) |
| Lung cancer | 1.28 (1.04 to 1.57) |
| Death from lung cancer | 1.46 (1.07 to 2) |
Beta-carotene and vitamin A supplements do not prevent cancer, and in smokers high-dose beta-carotene supplements have been shown to increase lung cancer and death — the exact opposite of what researchers set out to find [s1][s2]. The story is one of the clearest cautionary tales in nutrition: a real association between diets full of colourful produce and lower cancer risk did not survive being put in a pill [s1][s3].
Why anyone expected a benefit
The hypothesis was reasonable. Populations eating more carotenoid-rich fruit and vegetables, and people with higher blood levels of beta-carotene and vitamin E, had lower rates of lung cancer, and antioxidants can in principle mop up the reactive molecules involved in cancer and heart disease [s1][s3]. So two large randomised trials tested whether supplementing these nutrients in high-risk people would cut cancer. Both were rigorous, placebo-controlled, and — unusually — both were halted or reported findings that pointed the wrong way.
What the trials found
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study (ATBC) enrolled 29,133 male smokers aged 50 to 69 in Finland, assigning them alpha-tocopherol (vitamin E) 50 mg a day, beta-carotene 20 mg a day, both, or placebo, and followed them for five to eight years [s1]. There was no reduction in lung cancer from either supplement. Instead, the men taking beta-carotene had an 18 percent higher incidence of lung cancer (95 percent confidence interval, 3 to 36 percent) and 8 percent higher total mortality (95 percent confidence interval, 1 to 16 percent), driven by more deaths from lung cancer and heart disease [s1]. Vitamin E produced no change in lung cancer (a −2 percent difference, 95 percent confidence interval −14 to 12 percent) [s1].
The Beta-Carotene and Retinol Efficacy Trial (CARET) tested the combination directly, giving 18,314 smokers, former smokers and asbestos-exposed workers 30 mg of beta-carotene plus 25,000 IU of retinol (vitamin A) daily, against placebo [s2]. It was stopped 21 months early. The active-treatment group had a relative risk of lung cancer of 1.28 (95 percent confidence interval, 1.04 to 1.57), a relative risk of death from any cause of 1.17 (95 percent confidence interval, 1.03 to 1.33), and a relative risk of death from lung cancer of 1.46 (95 percent confidence interval, 1.07 to 2.00) [s2]. In plain terms, the supplement combination did not just fail to help — it appears to have harmed the very people it was meant to protect [s2].
Why food is not the same as the pill
The crucial distinction is between a nutrient in food and the same nutrient isolated at a high dose. Whole fruit and vegetables deliver beta-carotene alongside hundreds of other compounds, in modest amounts; the trials delivered it alone, at doses far above what diet supplies, to people whose lungs were already primed for cancer by decades of smoke or asbestos [s1][s2]. Nothing in these results argues against eating carotenoid-rich produce — the association that launched the whole effort was with diet, and it is the supplement, not the vegetable, that failed [s1][s3].
Where the guidance landed
The regulators absorbed the lesson. In 2022 the US Preventive Services Task Force recommended against the use of beta-carotene (and vitamin E) supplements for the prevention of cardiovascular disease or cancer, concluding with moderate certainty that for beta-carotene the harms outweigh the benefits — a formal "D" recommendation [s3]. It judged the evidence insufficient to recommend for or against multivitamins or most single nutrients [s3]. This matters because supplement use is near-universal: in US survey data, 52 percent of adults reported taking at least one dietary supplement in the previous month, and 31 percent a multivitamin [s3].
The same "isolate the antioxidant and hope" logic has been tested for other nutrients with similarly deflating results, most directly for selenium and cancer prevention. It is a recurring pattern across supplement trials — see our reviews of vitamin D in healthy adults and omega-3 fish oil — where a promising observational signal shrinks or vanishes in randomised trials, while the whole-food version, such as nuts and heart disease, tends to hold up better.
How to read this
This is settled, high-quality evidence, not a scare: two large randomised trials converged on the finding that beta-carotene supplements do not prevent cancer and can raise lung-cancer risk in smokers, and the guideline bodies now advise against them for prevention [s1][s2][s3]. The reasonable reading is that antioxidants belong on your plate, not in a high-dose capsule taken to ward off cancer. This article is informational and is not medical or dietary advice.
Sources
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers (ATBC) — New England Journal of Medicine , April 14, 1994
- Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease (CARET) — New England Journal of Medicine , May 2, 1996
- Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement — JAMA (US Preventive Services Task Force) , June 21, 2022
More on
Selenium and cancer: how a promising trial was overturned
A small 1990s trial hinted selenium supplements cut cancer, launching a supplement boom. The much larger SELECT trial found no benefit — and signals of harm, including more type 2 diabetes.
Adding immunotherapy to radiation did not help early-stage lung cancer survival
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
Vitamin A: lifesaving where children lack it, useless-to-risky where they don't
In deficient populations, vitamin A supplements cut child deaths by 12% — among the best-evidenced global-health interventions. In the well-nourished, added vitamin A does no good and can do harm.
Ivonescimab plus chemo extended survival in EGFR lung cancer after TKI failure
The final HARMONi-A analysis reports a 2.7-month gain in median overall survival — 16.8 versus 14.1 months — for the PD-1/VEGF bispecific added to chemotherapy in a China-only phase 3 trial.